Small biotech faces a crossroad

After fifteen years and $157 million in R&D expenses, Alseres execs say they are on to "one of the great miracles of science," according to this profile in the Boston Globe. Or not. Reorganized with new executives and a new financing round close to four years ago, Alseres has attracted considerable attention for two experimental drugs--Cethrin and Inosine. Cethrin hopefully blocks an enzyme that prevents the growth of new nerve fibers after a spinal column injury and Inosine, in animal tests, has stimulated brain rewiring after a stroke. In the meantime, the Globe piece notes, CEO Peter Savas has been taking home a handsome salary--$1.1 million last year in total compensation--while his company's future hinges on the near-term success of one of these drugs.

- read the article from The Boston Globe

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.